At Moffitt Cancer Center, we strive to be the leader in understanding the complexity of cancer and applying these insights to contribute to the prevention and cure of cancer. Our diverse team of over 9,000 are dedicated to serving our patients and creating a workspace where every individual is recognized and appreciated. For this reason, Moffitt has been recognized on the 2023 Forbes list of America’s Best Large Employers and America’s Best Employers for Women, Computerworld magazine’s list of 100 Best Places to Work in Information Technology, DiversityInc Top Hospitals & Health Systems and continually named one of the Tampa Bay Time’s Top Workplace. Additionally, Moffitt is proud to have earned the prestigious Magnet® designation in recognition of its nursing excellence. Moffitt is a National Cancer Institute-designated Comprehensive Cancer Center based in Florida, and the leading cancer hospital in both Florida and the Southeast. We are a top 10 nationally ranked cancer center by Newsweek and have been nationally ranked by U.S. News & World Report since 1999.
Working at Moffitt is both a career and a mission: to contribute to the prevention and cure of cancer. Join our committed team and help shape the future we envision.

Summary

We are seeking a highly motivated and talented Research Scientist to join our team, focusing on the validation of observations from fragment-based drug discovery screens using CRISPR and RNA interference in cancer models. The Research Scientist will play a crucial role in advancing our understanding of potential cancer drug targets identified through fragment-based drug discovery screens and chemical proteomics. This position offers a unique opportunity to contribute to translational research and the development of novel therapies for cancer treatment.

Responsibilities:

1. Validation of Drug Targets:
   • Design and execute CRISPR and RNA interference screening experiments to validate observations from fragment-based drug discovery screens.
   • Utilize molecular biology techniques to assess the impact of gene modulation on cancer cell behavior and response to potential drug candidates.
   • Utilize publicly available databases to provide additional data sets
2. Experimental Design and Optimization:
   • Develop and optimize protocols for CRISPR and RNA interference experiments tailored to specific drug targets.
   • Collaborate with oncologists, medicinal chemists and cancer biologists to ensure the relevance of screening assays.
3. Data Analysis and Interpretation:
   • Analyze and interpret screening data to validate the relevance of identified drug targets.
   • Collaborate with bioinformaticians to integrate screening results with other data sets for a comprehensive analysis.
4. Collaboration and Communication:
   • Work collaboratively with multidisciplinary teams, including medicinal chemistry, molecular biology, bioinformatics, and preclinical development.
   • Present findings at internal meetings, conferences, and contribute to publications.
5. Cell Line and Model Maintenance:
   • Maintain cancer cell lines and relevant in vivo models for validation experiments.
6. Instrumentation and Technology:
   • Operate and maintain cutting-edge laboratory equipment and technologies related to CRISPR and RNA interference.
   • Stay abreast of advancements in the field and recommend the integration of new technologies

Qualifications:

• Ph.D. in Molecular Biology, Cancer Biology, Genetics, or a related field with a minimum of three (3) years postdoctoral fellow or post PhD science experience in a relevant field is required.
• Proven expertise in CRISPR and RNA interference screening, particularly in the context of cancer biology.
• Strong molecular biology skills, including gene editing, nucleic acid isolation, and analysis.
• Excellent organizational, analytical, and communication skills.
• Ability to work collaboratively in a team-oriented environment.

How to Apply: Interested candidates should submit a cover letter, curriculum vitae to Eric.Haura@moffitt.org. Please include "Research Scientist - Validation of Drug Targets" in the subject line.